"Targeting Tumour Weakness: A Promising Breakthrough in Cancer Treatment"

Scientists have discovered a "vital weak spot" in certain types of cancers, linking DNA mutations in mitochondria to the effectiveness of immunotherapy drugs. By "rewiring" the DNA of mitochondria, tumors can become up to two and a half times more likely to respond to drugs like nivolumab. This breakthrough could help doctors identify which patients will benefit most from immunotherapy before starting treatment and potentially make treatment-resistant cancers more sensitive to these drugs. The technology behind the discovery is now being patented to develop new treatments that disrupt the energy sources cancer uses to spread and grow.